Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GXO Logistics Inc (GXO) vs Eli Lilly And Co (LLY) Price & Performance

GXO Logistics IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

GXO Logistics Inc vs Eli Lilly And Co — how do they compare? GXO Logistics Inc trades at $46.47 (market cap $5.32B), while Eli Lilly And Co trades at $1,174.03 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 195.5× GXO Logistics Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Eli Lilly And Co for 93 Days on average.

GXOLLY
Market Cap
$5.32B$1.04T
Volume
1,255,8163,064,878
Sector
IndustrialsHealth
52-Week High
$65.59$1.28K
52-Week Low
$44.17$799.57
Typical Hold Time
28 Days93 Days
Enterprise Value
$10.67B$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GXO Logistics Inc

GXO trades at $46.58, up 1.28% today, with a neutral technical signal and strong analyst support. The company reported three consecutive quarterly EPS beats and is expanding through strategic partnerships, including a new 10-year logistics deal with Columbia Sportswear in Europe. Revenue grew to $13.18B in 2025, with a net income margin of 0.96%, though valuation metrics like a P/E of 41.03 appear elevated relative to profitability.

The outlook is positive, driven by operational improvements and industry tailwinds, but risks include margin pressures and high debt. With an 89% buy rating from analysts and a consensus price target of $66.67, the stock offers significant upside potential if execution aligns with growth initiatives.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GXO

No sentiment data available yet.

LLY
22% Buy78% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About GXO Logistics Inc

GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.

Read more on GXO →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →